Trial
NCT06881251
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Dermatitis, Atopic
Intervention
Dupilumab
Why stopped
Terminated: futility criteria met at interim efficacy analysis.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-04